Among patients who stopped taking tirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% maintained their initial loss, with 55.2% in total maintaining or losing more weight
While the program provides access to other Lilly medications, currently, Eli Lillys Lilly Cares Foundation does not cover Zepbound
Using a diluent that doesn't actively prevent microbial growth means you're introducing an unpredictable variable that can quickly and irrevocably degrade your precious research material
Tirzepatide is typically administered once weekly as a subcutaneous injection, and your provider will guide you on proper injection techniques and dosage adjustments over time to minimize potential side effects
Contact your provider if symptoms are severe
This balanced approach guarantees both safety and therapeutic effectiveness while preserving patient autonomy in their treatment process